Chemical subgroup
L01EB – Epidermaler Wachstumsfaktor-Rezeptor (EGFR)-Tyrosinkinase-Inhibitoren
10Decisions
22Patient groups
Added benefit by patient group
- Major2
- Considerable2
- Minor1
- Not proven17
Decisions, newest first
- 2025-07-17LazcluzeLazertinibMinor
- 2025-07-03TagrissoOsimertinibNot proven: 2 of 2 patient groups
- 2025-02-06TagrissoOsimertinibNot proven
- 2024-12-19TagrissoOsimertinibMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2019-10-17VizimproDacomitinibNot proven: 2 of 2 patient groups
- 2019-01-17TagrissoOsimertinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2017-10-19TagrissoOsimertinibConsiderable
- 2016-10-20GiotrifAfatinibNot proven: 2 of 2 patient groups
- 2016-09-15TagrissoOsimertinibNot proven: 4 of 4 patient groups
- 2015-11-05GiotrifAfatinibMajor: 1 of 5 patient groupsNot proven: 4 of 5 patient groups
Data status: 2026-10-29